News | November 09, 2012

D3 Completes More Than 30,000 Advanced Treatment Plans, Commissions 100th Linear Accelerator

d3 logo

November 9, 2012 — The team of dosimetrists and physicists at D3 Oncology Solutions (D3), an affiliate of UPMC and UPMC CancerCenter, recently surpassed significant milestones: completing its 30,000th advanced treatment plan and commissioning its 100th linear accelerator.

"These milestones are significant for us because they reflect the continued confidence of our customers in the quality and efficiency of D3's services," said Kathy Lokay, president and CEO of D3.

Richard Lansberry, treatment planning manager, said, "D3 sets the industry standard for advanced treatment planning. Our core capabilities for centralized planning have been extended into the market through our training programs that help dosimetrists and physicists take their planning techniques to the next level of productivity and quality."

The collaborative nature of the training program can also be seen in other D3 services. From peer review to preparation for accreditation, to adoption of new technologies, D3's service model is bringing expertise to practices to enable local staff to confidently use advanced radiation techniques. An example is D3's Facilitated Commissioning product, which allows a local physicist to partner in the commissioning of a new linear accelerator, gaining first-hand experience at a lower cost while utilizing D3's expertise and proprietary tools.    

One of the key drivers of this collaborative commissioning approach was D3's development of their Diamond Dataset — the industry's first comprehensive catalogue of commissioning data from over 50 linear accelerators. By using this database, D3's physicists are able to significantly reduce the amount of data necessary to commission a new unit with no loss in the accuracy of the final beam models.  Results presented at the 2011 American Association of Physicists in Medicine (AAPM) conference confirmed that the Diamond Dataset dose models were within 1 percent of dose models generated from full commissioning data.

For more information:

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation